Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-39.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -58.63% |
| Return on Assets (Trailing 12 Months) | -37.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.97 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.63M |
| Free Float | 9.50M |
| Market Capitalization | $9.30M |
| Average Volume (Last 20 Days) | 5.68M |
| Beta (Past 60 Months) | 0.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.88% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |